Elixir Medical Corporation

You won’t want to miss this! Register today for our November 15th webinar,?“Acute Coronary Syndrome long-term outcomes: raising the bar” from 12-1pm CET (6-7am EST). We’ll be joined by a panel of experts who will discuss the latest INFINITY-SWEDEHEART RCT clinical data:?? - Stefan James, will discuss use of #DynamX* for patients with acute coronary syndrome? - Hee Hwa Ho will discuss singaporean experience with the primary PCI study - Case based discussions with Mirvat Alasnag, Dr. Tak Shun Chung, Dr. Micha? Hawranek, and Stephan Achenbach ??Register now:?https://lnkd.in/exnX423s *DynamX is CE marked. Not for sale in the U.S. #MedTech #Innovation PMN 2068 Rev A

ICYMI: PINNACLE I data demonstrated the safety and effectiveness of LithiX? Hertz Contact IVL for calcium fragmentation. LithiX showed 98.3% clinical success (primary effectiveness and safety endpoint) with 100% angiographic success across a range of moderate to severe calcium morphologies. ? Learn more about the results: https://lnkd.in/e3Pkt6nc ? Not approved in the U.S. ? #Lithotripsy #Cardiovascular #Medtech #Innovation PMN 2028 REV A

ICYMI: DynamX?* bioadaptor data show significant improvement over contemporary drug-eluting stents in?patients with acute coronary syndrome and complex lesion subsets after six months. View the results: https://lnkd.in/etYST6ap *CE marked. Not for sale in the U.S. #Cardiovascular #Medtech #Innovation PMN 2066 REV A

INFINITY-SWEDEHEART 12-month data assessing DynamX?* versus contemporary drug-eluting stent is now published in The Lancet Group! Congratulations to the team and thank you to everyone who has helped this come to fruition, including Drs. David Erlinge, Jonas Andersson, Ole Frobert, Mattias T?rnerud, Mehmet Hamid, Thomas Kellerth, and all other investigators involved in the study.? View the article here: https://lnkd.in/etYST6ap *CE marked. Not for sale in the U.S. #MedTech #Innovation #TCT PMN 2036 Rev A

Register today for our November 15th webinar,? “Acute Coronary Syndrome long-term outcomes: raising the bar” from 12-1pm CET (6-7am EST). ??Stephan Achenbach and Mirvat Alasnag will moderate this case-based discussion. We’ll be joined by a panel of experts using #DynamX:?? - Stefan James, will present the latest INFINITY-SWEDEHEART RCT clinical data for patients with acute coronary syndrome. 83% (significant) reduction in TLF in patients with Acute Coronary Syndrome was demonstrated by INFINITY SWEDEHEART RCT presented at #TCT2024? - Hee Hwa Ho will discuss singaporean experience with the primary PCI study - Dr. Tak Shun Chung and Dr. Micha? Hawranek will present their cases with #DynamX ??Register now: https://lnkd.in/exnX423s *DynamX is CE marked. Not for sale in the U.S. #MedTech #Innovation PMN 2038 Rev A

??NEW DATA: PINNACLE I trial data demonstrate safety and effectiveness of LithiX? Hertz Contact IVL for calcium fragmentation in a broad complex range of calcium morphologies. ? 98.3% clinical success (primary effectiveness and safety endpoint) with 100% angiographic success across a range of moderate to severe calcium morphologies. ? LithiX HC-IVL offers a safe, effective approach for calcium fragmentation to optimize stent implantation?without a need for external energy source. The system also offers a simplified IVL workflow and learning curve. Learn more about the results at https://lnkd.in/e3Pkt6nc Not approved in the U.S. PMN 2062 Rev A

Simultaneous publication in The Lancet of the late-breaking RCT clinical data demonstrating significant benefit of the DynamX? Coronary Bioadaptor System compared to contemporary drug-eluting stent for target lesion failure in complex patient population subsets from the 2400 patients INFINITY-SWEDEHEART RCT. The data included an analysis of patients with acute coronary syndrome (ACS), small vessel lesions, and lesions within the left anterior descending (LAD) artery. #TCT2024

??NEW DATA: INFINITY-SWEDEHEART RCT 12-month outcomes comparing #DynamX?* with a contemporary DES in patients with acute coronary syndrome and complex lesion subsets after six months. ?? Landmark analysis (6-12 months) showed DynamX bioadaptor significantly reduces adverse events compared to DES, confirming unique mechanism of action after unlocking at 6 months ?? Clinical results in patients with ACS demonstrated 83% reduction (0.3% vs. 1.8%; (p<0.018)) in TLF rate ?? Clinical results in patients with lesions in the LAD vessels demonstrated 73% reduction (0.2% vs. 2.2%) in TLF rate ?? There were no TLF events in patients with small vessels (less than or equal to 2.75 mm) in the DynamX arm Learn more about the results: https://lnkd.in/etMwb9XZ INFINITY-SWEDEHEART data were published concurrently in The Lancet: https://lnkd.in/etYST6ap *CE marked. Not for sale in the U.S. #Cardiovascular #Medtech #Innovation #TCT2024 PMN 2032 REV A

??? Mark your calendar! We’ll be sharing new clinical data on two transformative platforms at #TCT2024! ?? #DynamX* bioadaptor - We’ll share late-breaking data from ACS population and complex lesion subsets in the INFINITY-SWEDEHEART RCT, a large (2,400-patient) randomized trial in a representative patient population including evaluating the use of the #bioadaptor in more complex clinical setting ?? #LithiX** - We’ll share full six-month & OCT imaging sub-study data from our PINNACLE I Trial evaluating the safety and effectiveness of this novel Hertz contact lithotripsy system over a broad range of calcium morphologies Learn more about our full session line up and visit us at booth #2823: https://lnkd.in/dKFSaPfu ? *DynamX is CE marked. Not approved in the U.S. ? **LithiX is not approved in the U.S. ? #MedTech #Innovation #TCT #cardiovascular #hearthealth ? PMN 2022 Rev A

Join us at #OptimaLondon2024 in London on October 7– 8, 2024. ? Don't miss #DynamX? Bioadaptor at “Innovation Alley” featuring expert physician insights from Drs. Colm Hanratty, Rasha Al-Lamee, Jonathan Hill, Angela McInerney. ? Come learn more and interact with our innovative technology!? ? Optima Education Ltd?James Spratt.? ? CE marked. Not for sale in the U.S. ? #MedTech #Innovation? ? PMN 2034 Rev A